Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Candel Therapeutics's profit margin for the twelve months ending Dec 31, 2022 was -15035.2%. For fiscal 2022 it was -15035.2%, against -28899.2% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -15035.2% | +13864.0 |
| FY2021 | Dec 31, 2021 | -28899.2% | −14755.2 |
| FY2020 | Dec 31, 2020 | -14144.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -16396.8% | −21545.2 |
| Q3 FY2022 | Sep 30, 2022 | -28025.8% | +24109.7 |
| Q2 FY2022 | Jun 30, 2022 | -13383.9% | +41712.9 |
| Q1 FY2022 | Mar 31, 2022 | -2819.4% | +11625.8 |
| Q4 FY2021 | Dec 31, 2021 | 5148.4% | +38948.4 |
| Q3 FY2021 | Sep 30, 2021 | -52135.5% | −43896.8 |
| Q2 FY2021 | Jun 30, 2021 | -55096.8% | −45819.4 |
| Q1 FY2021 | Mar 31, 2021 | -14445.2% | – |
| Q4 FY2020 | Dec 31, 2020 | -33800.0% | – |
| Q3 FY2020 | Sep 30, 2020 | -8238.7% | – |
| Q2 FY2020 | Jun 30, 2020 | -9277.4% | – |
See a number that looks wrong?